Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 4
1986 2
1987 1
1988 5
1989 5
1990 6
1991 1
1992 3
1993 7
1994 5
1995 5
1996 2
1997 2
1998 3
1999 6
2000 4
2001 7
2002 3
2003 5
2004 7
2005 6
2006 5
2007 6
2008 8
2009 13
2010 9
2011 16
2012 24
2013 12
2014 23
2015 22
2016 18
2017 12
2018 9
2019 8
2020 8
2021 12
2022 10
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. Ogbuagu O, et al. Among authors: podzamczer d. Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. Lancet HIV. 2021. PMID: 34197772 Clinical Trial.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Among authors: podzamczer d. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
[Introduction. Rilpivirine].
Podzamczer D. Podzamczer D. Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:1. doi: 10.1016/S0213-005X(13)70135-6. Enferm Infecc Microbiol Clin. 2013. PMID: 24252526 Spanish. No abstract available.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Among authors: podzamczer d. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
Past and future of HIV infection. A document based on expert opinion.
Bouza E, Arribas JR, Alejos B, Bernardino JI, Coiras M, Coll P, Del Romero J, Fuster MJ, Górgolas M, Gutiérrez A, Gracia D, Hernando V, Martínez-Picado J, Martínez Sesmero JM, Martínez E, Moreno S, Mothe B, Navarro ML, Podzamczer D, Pulido F, Ramos JT, Ruiz-Mateos E, Suárez García I, Palomo E. Bouza E, et al. Among authors: podzamczer d. Rev Esp Quimioter. 2022 Apr;35(2):131-156. doi: 10.37201/req/083.2021. Epub 2022 Jan 12. Rev Esp Quimioter. 2022. PMID: 35018404 Free PMC article. Review.
Switching strategies in the recent era of antiretroviral therapy.
Prieto P, Podzamczer D. Prieto P, et al. Among authors: podzamczer d. Expert Rev Clin Pharmacol. 2019 Mar;12(3):235-247. doi: 10.1080/17512433.2019.1575728. Epub 2019 Feb 13. Expert Rev Clin Pharmacol. 2019. PMID: 30691315 Review.
Switch strategies in antiretroviral therapy regimens.
Van den Eynde E, Podzamczer D. Van den Eynde E, et al. Among authors: podzamczer d. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1055-74. doi: 10.1586/14787210.2014.944506. Epub 2014 Jul 30. Expert Rev Anti Infect Ther. 2014. PMID: 25075752 Review.
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).
Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: podzamczer d. J Immunother Cancer. 2021 Mar;9(3):e001664. doi: 10.1136/jitc-2020-001664. J Immunother Cancer. 2021. PMID: 33782108 Free PMC article. Review.
Once-daily antiretroviral therapy: Spanish Consensus Statement.
Pulido F, Ribera E, Moreno S, Muñoz A, Podzamczer D, del Pozo MA, Rivero A, Rodríguez F, Sanjoaquín I, Teira R, Viciana P, Villalonga C, Antela A, Carmena J, Ena J, Gonzalez E, Kindelán JM, Mallolas J, Márquez M, Martínez E. Pulido F, et al. Among authors: podzamczer d. J Antimicrob Chemother. 2005 Nov;56(5):808-18. doi: 10.1093/jac/dki320. Epub 2005 Sep 8. J Antimicrob Chemother. 2005. PMID: 16150862
285 results